| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
XOMA Royalty Corporation$44.8
-0.7 (-1.56%)
B 60Pipeline Score Undervalued Pharma · Commercial
Market Cap
522.33 M
EPS
1.65
P/E Ratio
26.51 $
Value Trade
2.82 M
SEC Financials
Q1 2026Dilution Risk
Revenue
12.32 M
R&D Expenses
49.00 K
Operating CF
6.12 M
Total Assets
271.86 M
Total Liabilities
158.96 M
Equity
92.88 M
D/E Ratio
12,345
-0.45 %
Week
4.46 %
1 Month
70.35 %
3 Month
31.35 %
6 Month
31.6 %
5 Year
-99.18 %
All Time
Cash Data
Cash Position
111.10 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
375.68 K
52 Week Range
22.29 - 42.81
% held by Insiders
2.33 %
% held by Institutions
84.96 %
Enterprise Value
572.18 M
Total Shares
12.39 M
Short %
7.38 %
Float Shares
12.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for XOMA Royalty Corporation
435Total events
9Upcoming
161Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 9
2027
T2Quarterly Update
Ligand expects acquisition to be accretive by $1.50 per share to adjusted EPS in 2027
TBD
T1IP Litigation Ruling
Ongoing litigation against Janssen Biotech for unauthorized use of XOMA IP in TREMFYA commercialization
2026-H2
T1Topline Readout
Rezolute expects topline results from Phase 3 upLIFT trial of ersodetug in tumor HI
Event history 426
Q3 2026
◆Timing GuidanceersodetugPresentation
Product launch of ersodetug for HI expected in 2H26
Hyperinsulinism (HI)source ↗
Apr 28, 2026
Apr 27, 2026
Q2 2026
◆Timing GuidancevolixibatPresentation
Data announcement for volixibat in PSC expected in 2Q26
Primary Sclerosing Cholangitis (PSC)source ↗
Q2 2026
◆Topline ReadoutvolixibatClinical Data
Phase 2b data from volixibat in PSC expected in Q2 2026
PSCsource ↗
Mar 18, 2026
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update webcast
Drug Pipeline Intelligence
B60
Pipeline Score $2.1B
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored4.0x
rNPV / MCap Top 87%
Micro Cap (rank 119 of 906)
Percentile RankXOMA Royalty Corporation holds a solid B-grade pipeline (60/100), with $10.5B risk-adjusted pipeline value, led by XOMA 052 in Type 2 Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XOMA 052 Small molecule | Type 2 Diabetes Mellitus | Phase 2 | NCT01144975 | 43% | $9.1B | COMPLETED | 497 | - | - | Oct 1, 2011 | - | May 16, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XOMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XOMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XOMAXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
XOMA Royalty Corporation has declared cash dividends for its Series A and B preferred stockholders, set for payment on July 15, 2026. The company will also redeem all outstanding preferred shares on July 14, 2026, as part of a merger with Ligand Pharmaceuticals. Additionally, a record date for contingent value rights distribution has been established for July 13, 2026.
Read more →XOMAXOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm
The Schall Law Firm is investigating XOMA Royalty Corporation for potential breaches of fiduciary duty by its directors and management. This comes in light of the company's announced acquisition by Ligand Pharmaceuticals for $739 million. The investigation aims to determine if the board acted in the best interests of shareholders. Shareholders are encouraged to participate in the investigation and assess their rights regarding this potential misconduct.
Read more →XOMA▲ +10.7%on this newsshared move
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals announced its acquisition of XOMA Royalty for $39.00 per share, totaling approximately $739 million. This acquisition will expand Ligand's portfolio to over 200 assets, adding seven commercial products and enhancing its growth potential. The deal is expected to be immediately accretive to earnings per share, with increased guidance for 2026. The transaction is set to close in Q3 2026, pending regulatory approvals.
Read more →XOMAXoma Royalty Corporation Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Xoma Royalty Corporation for potential securities fraud. This comes after a significant decline in Xoma's stock price, which fell by 22.76% following the announcement of clinical trial failures related to its therapeutic candidate, ersodetug. The trial did not achieve its primary endpoint and showed no statistically significant improvement over a placebo. As a result, investor confidence has been severely impacted, prompting legal actions for potential recovery of losses.
Read more →XOMAXOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation has announced a cash dividend for holders of its Series A and B preferred stock. The Series A Cumulative Perpetual Preferred Stock will yield $0.53906 per share, while depositary shares of Series B will pay $0.52344 per share. These dividends are scheduled to be paid on April 15, 2026, to those on record by April 2, 2026. XOMA Royalty continues to support biotechnology through its portfolio of milestone and royalty rights, enhancing funding for biotech firms.
Read more →XOMAXOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements Portfolio receipts : Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones,
XOMA Royalty Corporation reported its 2025 financial results, achieving over $50 million in cash receipts, driven primarily by a significant rise in royalties. The company added 22 assets to its portfolio, including several in late-stage development, and undertook multiple acquisitions. However, increasing General and Administrative expenses and ongoing litigation against Janssen Biotech present potential risks. XOMA anticipates further catalysts in 2026 that could enhance shareholder value.
Read more →XOMAXOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
XOMA Royalty Corporation has announced that it will report its fourth quarter and full year 2025 financial results on March 18, 2026. A webcast will be held on the same day at 8:00 am Eastern Time to discuss these results and provide a business update. The webcast will be available on the company's website, with a replay accessible for 30 days.
Read more →XOMACORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking stat
XOMA Royalty has released a corporate presentation outlining its strategic focus on biotechnology royalty aggregation, emphasizing future monetization opportunities and a growing portfolio. The presentation includes details about its financial performance and upcoming milestones for several drugs in development. However, it also notes the ongoing litigation against Janssen, which could impact financial forecasts. Additionally, the company's forward-looking statements come with risks, reflecting the uncertain nature of the biotechnology field.
Read more →XOMAXOMA Royalty to Present at Investor Conferences in March
XOMA Royalty Corporation has announced that members of its Executive Team will participate in several investor conferences in March 2026. The conferences include the T.D. Cowen 46th Annual Health Care Conference and the Leerink 2026 Global Healthcare Conference. These events will feature management in fireside chats and one-on-one meetings with investors. XOMA aims to enhance its visibility and attract potential investors through these engagements.
Read more →XOMAXOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
XOMA Royalty Corporation has completed its acquisition of Generation Bio, successfully tendering approximately 70% of the outstanding shares at a price of $4.2913 per share. Following the tender offer's expiration, Generation Bio has become a wholly owned subsidiary of XOMA Royalty. The shares of Generation Bio will be delisted from Nasdaq as part of this acquisition.
Read more →XOMA▼ -10.3%on this news
XOMA Royalty Announces CFO Transition
XOMA Royalty Corporation announced the resignation of its Chief Financial Officer, Thomas Burns, who is leaving to pursue other opportunities. Burns has been with the company for nearly two decades, contributing greatly to its establishment as a biotech royalty aggregator. The company has appointed Jeffrey Trigilio as the new CFO, who brings a wealth of experience from various roles in biotech and finance. XOMA Royalty continues to strengthen its position in the market with a promising portfolio of assets that is expected to yield future revenue.
Read more →XOMA▼ -10.3%on this news
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR NASDAQ COMMON: XOMA FOR BIOTECH NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO COMPANIES JANUARY 2026 DISCLAIMERS Certain statements in this presentation are forward-looking
XOMA Royalty has released a presentation outlining the company's business strategy and financial outlook. The document highlights upcoming potential milestones and the diversifying royalty portfolio expected to drive future revenue. However, it also includes disclaimers about the inherent risks in the biotechnology industry, which could affect the accuracy of forward-looking statements. Investors are cautioned to consider these risks carefully as XOMA pursues its plans in a regulated market.
Read more →XOMAXOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
XOMA Royalty Corporation has amended its collaboration with Takeda, regaining a majority of royalty interest in mezagitamab. The new agreement reduces Takeda's payment obligations while allowing XOMA to receive payments from nine development-stage assets. This strategic move aims to diversify XOMA's portfolio and enhance its revenue potential, despite a reduction in specific royalty entitlements.
Read more →XOMAXOMA Royalty Enters into Agreement to Acquire Generation Bio
XOMA Royalty has announced an agreement to acquire Generation Bio for $4.2913 per share, which will include potential milestone and royalty payments from Generation Bio's collaboration with Moderna. The acquisition, expected to close in February 2026, has been unanimously approved by Generation Bio's board and supported by stockholders holding 15% of the company's shares. However, the deal is contingent upon meeting certain conditions, including a majority of shares being tendered. There are risks associated with the completion and potential financial outcomes of the merger.
Read more →XOMAXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc, following approval from Mural's shareholders and the Irish High Court. Shareholders received $2.035 in cash per share as part of the transaction. Mural's shares will cease trading on Nasdaq and will be delisted. This acquisition is expected to strengthen XOMA's position in the biotech sector.
Read more →XOMAXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics, acquiring all outstanding shares. Shareholders received cash and contingent value rights linked to future earnings from LAVA's assets. This acquisition is expected to enhance XOMA's portfolio and create value for shareholders through collaborations with major pharmaceutical companies. The trading of LAVA shares has been suspended as part of the reorganization.
Read more →XOMAXOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
XOMA Royalty Corporation reported its third quarter and year-to-date financial results for 2025, highlighting a significant increase in income and royalties received. The company secured royalty interests in two partnered assets and completed several acquisitions, including LAVA Therapeutics. Despite increased R&D expenses, the outlook remains positive with anticipated clinical readouts that could impact future growth.
Read more →XOMAXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty and LAVA Therapeutics have amended their share purchase agreement, adjusting the cash amount and contingent value rights for LAVA shareholders. The cash offer has been reduced to $1.04 per share, with additional rights to receive cash payments based on future proceeds. The tender offer has been extended to November 12, 2025, allowing more time for shareholder participation. Closing is expected in Q4 2025, subject to customary conditions.
Read more →XOMAXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty Corporation has extended its tender offer for LAVA Therapeutics N.V. until October 17, 2025. The offer includes cash and contingent value rights tied to LAVA's partnered assets. Shareholder support is strong, but the acquisition is subject to conditions such as the tender of at least 80% of shares. The deal is expected to close in Q4 2025.
Read more →XOMAXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
XOMA Royalty Corporation has successfully completed its tender offer for HilleVax, Inc., acquiring 77.48% of its outstanding shares at $1.95 each. Following the tender offer, HilleVax has merged with a subsidiary of XOMA, becoming a wholly owned entity. The shares of HilleVax will cease trading on Nasdaq and will be delisted.
Read more →XOMAXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
XOMA Royalty Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Owen Hughes and CIO Brad Sitko will provide updates on the company's activities. The presentation will be accessible via webcast and through the company's investor relations website.
Read more →XOMAMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
Mural Oncology has entered into a definitive agreement to be acquired by XRA 5 Corp., a subsidiary of XOMA Royalty, for a cash price between $2.035 and $2.24 per share. This acquisition, approved by both companies' boards, aims to maximize shareholder value following a strategic review. However, the final cash amount is contingent on Mural's closing net cash exceeding estimates, and the deal is subject to shareholder approval and other conditions.
Read more →XOMA▲ +8.5%on this news
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent Internat
XOMA Royalty reported its second quarter financial results for 2025, highlighting substantial progress in business development and acquisitions. The company acquired rights to mezagitamab and partnered with LAVA Therapeutics, which is projected to enhance its royalty income. XOMA's cash receipts reached $29.6 million in the first half of 2025, reinforced by milestone payments from various partners. These accomplishments reflect a commitment to a diversified portfolio and potential for increased shareholder value.
Read more →XOMAXOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
XOMA Royalty Corporation has completed its tender offer for Turnstone Biologics, acquiring shares at $0.34 each plus a contingent value right. Approximately 74% of Turnstone's outstanding shares were tendered. Following the acquisition, Turnstone has merged into a subsidiary of XOMA and will cease trading on Nasdaq. The transaction aims to enhance XOMA's portfolio in the biotech sector.
Read more →XOMA▲ +10%on this news
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty Corporation has entered into a definitive agreement to acquire LAVA Therapeutics for a cash price between $1.16 and $1.24 per share, along with a contingent value right. The acquisition aims to benefit both companies' shareholders by leveraging LAVA's partnered programs. The transaction is expected to close in the fourth quarter of 2025, pending certain conditions.
Read more →XOMAXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
XOMA Royalty Corporation has acquired royalty and milestone rights for mezagitamab from BioInvent International for up to USD $30 million, enhancing its late-stage portfolio. The deal involves an initial payment of USD $20 million with an additional USD $10 million to be paid upon achievement of a specific milestone. The transaction is seen as beneficial for both companies, providing BioInvent with non-dilutive capital to support its clinical development efforts. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab, indicating the potential for significant future returns.
Read more →XOMA▲ +10.9%on this news
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements Pipeline advancements : The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen s tovorafenib
XOMA Royalty Corporation reported its financial results for Q1 2025, highlighting key advancements in its pipeline and business developments. The Marketing Authorization Application for tovorafenib was accepted for review by the EMA, alongside the initiation of Takeda's Phase 3 trial for mezagitamab. The company achieved significant revenue growth, receiving $18 million in cash, including royalties and milestone payments. Despite rising R&D costs, XOMA remains optimistic about generating sustainable cash flow from its royalty interests.
Read more →XOMA▲ +6.3%on this news
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
XOMA Royalty Corporation will have its CEO Owen Hughes and CIO Brad Sitko present at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025. They will participate in various discussions focusing on the royalty model and its applications within the biotech sector. Additionally, XOMA will attend the BioConnect Investor Conference in New York on May 20, 2025, furthering its engagement with industry stakeholders.
Read more →XOMAXOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty Corporation has finalized the sale of all five pipeline assets acquired from Kinnate Biopharma Inc. for up to $270 million, including milestone payments and royalties on future sales. This agreement allows holders of Kinnate Contingent Value Rights to earn 85% of related payments until April 2029. The transaction is expected to enhance financial prospects for XOMA and its shareholders, although risks involved in the development and commercialization of the assets remain.
Read more →XOMAXOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
XOMA Royalty Corporation announced that Chief Investment Officer Brad Sitko will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The event highlights XOMA's role in supporting biotech companies by acquiring potential future economics from their therapeutic candidates. Attendees can access the presentation online, and a replay will be available for 90 days post-event. This opportunity is expected to enhance XOMA's visibility and potentially engage with investors.
Read more →XOMAXOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential th
XOMA Royalty Corporation reported strong financial results for the fourth quarter and full year of 2024, highlighting its expansion in royalty and milestone portfolios through strategic acquisitions. With FDA approvals for two significant therapeutic agents, the company anticipates enhanced income and positive cash flow moving forward. Total income nearly doubled year-over-year, reflecting a successful year in royalty monetization and asset growth. Despite increasing expenses associated with acquisitions and clinical trials, XOMA remains well-positioned for continued growth in the biopharma landscape.
Read more →XOMAXOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
XOMA Royalty Corporation will have members of its Executive Team present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025. CEO Owen Hughes and CIO Brad Sitko will participate in a fireside chat on February 11 at 3:20 PM ET. The conference will be held virtually, and presentations will be accessible on the company's investor relations website, with replays available for 90 days post-event.
Read more →XOMAXOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio Seralutinib becomes XOMA Royalty s seventh Phase 3 royalty asset, further buildi
XOMA Royalty Corporation has acquired Pulmokine Inc. for $20 million, gaining rights to seralutinib, a Phase 3 asset being developed for pulmonary arterial hypertension (PAH). This acquisition increases XOMA's portfolio to seven Phase 3 royalty assets. The acquisition allows XOMA to potentially earn low to mid-single digit royalties on sales and up to $25 million in milestone payments linked to seralutinib's development. The drug may also have future applications beyond PAH, according to XOMA's Chief Investment Officer.
Read more →XOMA▼ -7%on this news
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra s MIPLYFFA (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty s portfolio XOMA Royal
XOMA Royalty Corporation has reported its financial results for the third quarter of 2024, during which it highlighted key developments including the FDA approval of Zevra's MIPLYFFA for Niemann-Pick disease type C and a royalty monetization agreement with Twist Bioscience. The company generated $9.9 million in cash receipts and recorded total income of $7.2 million, significantly higher than the previous year. However, it faced a net loss of $17.2 million, influenced by a non-cash impairment related to an existing royalty agreement.
Read more →XOMAXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience XOMA Royalty has acquired 50 percent of Twist s existing royalty and mileston
XOMA Royalty Corporation has entered a $15 million agreement to acquire a 50% economic interest in over 60 early-stage programs from Twist Bioscience. This expansion increases XOMA’s portfolio to more than 100 assets, ranging from revenue-generating therapeutics to pre-clinical programs. The company aims to create value through diverse revenue streams and plans further disciplined capital deployment. The agreement is positioned to bolster XOMA’s unique role in the biotech royalty sector, aligning with their strategy to support innovation in healthcare.
Read more →XOMAZevra s MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) MIPLYFFA is the first therapy approved for use in patients with NPC, a ra
Zevra Therapeutics has received FDA approval for MIPLYFFA (arimoclomol) for treating Niemann-Pick Disease Type C, marking it as the first therapy approved for this rare condition. The approval allows MIPLYFFA to be used in combination with miglustat in patients aged two years and older. As part of this development, XOMA Royalty is entitled to receive a mid-single digit royalty on future sales of MIPLYFFA, along with potential milestone payments totaling up to $52.6 million. This event enhances XOMA's portfolio, which now includes six commercial assets.
Read more →XOMAXOMA Royalty to Present at Upcoming Investor Conferences in September
XOMA Royalty Corporation, a biotech royalty aggregator, has announced its participation in two upcoming investor conferences in September 2024. The Executive Team, led by CEO Owen Hughes and CIO Brad Sitko, will present at the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 Cantor Global Healthcare Conference. These presentations aim to provide insights into the company's operations and corporate overview. Interested parties can access the presentations online, and recordings will be available for 90 days post-event.
Read more →XOMA▲ +14.4%on this news
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolut
XOMA Royalty Corporation reported its financial results for the second quarter of 2024, showing cash receipts of $22.6 million, driven by royalties and milestone payments. The company highlighted its recent acquisitions, including new commercial assets and the completion of Kinnate Pharmaceuticals acquisition, which add potential royalty streams and strengthened its cash position. However, increased administrative costs and a one-time impairment charge were noted as financial challenges amid overall improved performance.
Read more →XOMAXOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities Earned $9 million milestone upon U.S. Food and Drug Administration s approval of Day One s OJEMDA (tovorafenib); XOMA is entitled to rece
XOMA Corporation reported its financial results for the first quarter of 2024, highlighting key activities including the FDA approval of Day One's OJEMDA, which earned the company a $9 million milestone payment. The company also acquired Kinnate Pharmaceuticals, adding over $9 million in non-dilutive capital to its balance sheet, and launched a stock repurchase program of up to $50 million. Despite a net loss of $8.6 million for the quarter, XOMA continues to expand its royalty portfolio and focus on strategic capital deployment.
Read more →XOMAXOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% Organon, a global women s healthcare company, initiated XACIA
XOMA Corporation has announced the acquisition of economic interests in three women’s health assets, including the FDA-approved XACIATO vaginal gel, for an upfront payment of $22 million. The deal also includes two investigational assets, Ovaprene and Sildenafil Cream, both of which have potential as first-in-category treatments. This acquisition expands XOMA’s royalty and milestone portfolio, highlighting its commitment to investing in under-represented areas of women's health. The partnership enables Dar Bioscience to enhance its pipeline while providing XOMA with royalty rights on future sales.
Read more →XOMAXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One s OJEMDA TM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) XOMA is entitled to a mid-single digit roy
XOMA Corporation announced that it has earned a $9 million milestone following the FDA's accelerated approval of Day One Biopharmaceuticals' OJEMDA (tovorafenib) for treating pediatric patients with relapsed or refractory low-grade glioma harboring BRAF alterations. This marks a significant advancement for XOMA’s royalty portfolio and provides a treatment option for children suffering from this condition. The approval of OJEMDA is noteworthy as it is the first of its kind for this patient subgroup, underscoring the therapy's relevance and potential impact on patient care.
Read more →XOMAXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value Raised up to $140 million of non-dilutive non-recourse capital through a roya
XOMA Corporation reported its fourth quarter and full year 2023 financial results, highlighting a substantial $140 million raised through a royalty-backed loan. The company noted milestones including cash payments of $15.5 million associated with its growing royalty base, and it added a third commercial asset, DSUVIA, to its portfolio. However, XOMA reported a significant net loss of $40.8 million for the year and faced impairment charges alongside increased general and administrative expenses.
Read more →XOMAXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its bala
XOMA Corporation has announced its agreement to acquire Kinnate Biopharma for a cash price per share ranging between $2.3352 and $2.5879, plus potential contingent value rights. This move is aimed at bolstering XOMA's cash reserves and expanding its royalty portfolio with Kinnate's early-stage oncology programs. The deal has been unanimously approved by Kinnate's Board of Directors and is projected to close in April 2024, pending certain conditions such as securing a majority of shareholder support and financial readiness.
Read more →XOMAXOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition
XOMA Corporation has acquired an economic interest in DSUVIA, a sublingual pain management tablet, from Talphera for $8 million. The deal allows XOMA to receive a 15% royalty on commercial sales and potentially up to $116.5 million in milestone payments. The acquisition aligns with XOMA's strategy of obtaining royalty economics that offer attractive risk/reward profiles while providing an effective solution for managing severe acute pain in medically supervised settings.
Read more →XOMA▲ +12.9%on this news
XOMA Announces Stock Repurchase Program of up to $50 Million Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive t
XOMA Corporation has announced a stock repurchase program that permits the company to buy back up to $50 million of its common stock through January 2027. This program is part of a balanced capital allocation strategy aimed at returning capital to shareholders while still investing in royalty and milestone acquisitions. The management retains discretion over the timing and conditions under which shares may be repurchased, depending on market conditions and acquisition opportunities. This program marks the first of its kind for XOMA under its current leadership.
Read more →XOMA▲ +16.2%on this news
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties Low-cost financing capitalizes on XOMA s $14 million acquisition of VABYSMO (faric
XOMA Corporation has announced that it secured non-dilutive, non-recourse financing of up to $140 million from Blue Owl Capital, which will be supported by royalties from VABYSMO (faricimab). The funds are aimed at stock repurchases and further acquisitions of royalty and milestone interests. This financing comes at a strategically beneficial time to bolster XOMA's portfolio, which includes products in advanced development stages. XOMA has drawn $130 million already, with conditions for additional funding based on VABYSMO sales performance.
Read more →XOMA▼ -6.4%on this news
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certa
XOMA Corporation reported its third quarter 2023 financial results, highlighting a total revenue of $0.8 million, an increase from the previous year. The company received $6.6 million from royalties and milestone payments, and filed a New Drug Application (NDA) for tovorafenib, with another NDA anticipated by year-end. Despite a net loss of $5.5 million for the quarter and rising general and administrative expenses, XOMA expects continued growth from its royalty portfolio. The company remains optimistic about its cash sufficiency to fund operations for multiple years.
Read more →XOMAXOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-read
XOMA Corporation reported its second quarter 2023 financial results and provided updates on its royalty monetization strategy. The company has successfully completed two royalty acquisitions, adding a cash-generating asset and an NDA-ready asset. XOMA expects at least one partner to file a New Drug Application in the third quarter of 2023. However, the company also faced challenges, such as a non-cash impairment charge linked to the suspension of Bioasis operations and a forecast of lower cash receipts from milestones than initially expected.
Read more →XOMAXOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
XOMA Corporation announced the acquisition of royalty and milestone rights for two therapeutic assets from LadRx Corporation, including arimoclomol for Niemann-Pick Disease Type C and aldoxorubicin for oncology. Arimoclomol is in the final stages of clinical development and has received several designations from the FDA aimed at accelerating its review process. This strategic acquisition supports XOMA's goal of addressing significant unmet medical needs while generating potential cash flow for the company. The deal includes up to $52.6 million in milestone payments and a royalty on commercial sales of the assets.
Read more →XOMAXOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy First quarter with incoming cashflows from two commercial assets Completed fir
XOMA Corporation has reported its first quarter financial results for 2023, showing a focus on accelerating its royalty monetization strategy. The company generated $0.4 million in revenues, a decline from the previous year's $3.1 million, resulting in a net loss of $9.8 million. XOMA successfully added cashflow-generating assets to its portfolio and completed its first royalty asset acquisition under new leadership. However, the company also faced increased expenses and arbitration settlement costs during the quarter.
Read more →XOMAXOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
XOMA Corporation has acquired the commercial payment and part of the milestone rights to IXINITY from Aptevo Therapeutics for $9.6 million. This acquisition is projected to provide XOMA with a consistent cash flow stream and enhance its royalty aggregation strategy. IXINITY is already established in the treatment of Hemophilia B, with potential for further growth in both market and geographic reach. XOMA will begin receiving payments from IXINITY sales starting January 2023.
Read more →XOMA▲ +5.8%on this news
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy 2022 was the first year with cash receipts from a commercial asset since becoming
XOMA Corporation reported its full-year 2022 financial results, which included an increase in net loss to $17.1 million compared to previous gains. The company highlighted the first year with cash receipts from a commercial asset, alongside a projected income from two commercial assets expected by 2024. The report emphasized the acquisition of a license for Ebopiprant, which could yield up to $378 million. Despite rising general and administrative expenses and uneven cash flows anticipated in the coming years, XOMA remains focused on enhancing shareholder value through strategic acquisitions.
Read more →XOMA▲ +15.9%on this news· ran to +34% by day 1
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales milestones Low- to mid- teens royalties up
Read more →XOMAXOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related ma
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
Read more →XOMA▼ -6.6%on this news
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events The completion of Regeneron s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July. Data from Rez
Read more →XOMAXOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has an
Read more →XOMA▲ +11.5%on this news· ran to +23% by day 1
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million f
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a si
Read more →XOMAXOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the
Read more →XOMAXOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Jan
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combinat
Read more →XOMAXOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist pa
Read more →XOMAXOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events XOMA s portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quart
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events XOMA s portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash. The April 2021 $40
Read more →XOMAXOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (Nasdaq: AFMD) innate cell engager (ICE®) programs for which
Read more →XOMAXOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights Recognized revenue of $29.4 million Six assets in the Company s milestone and royalty portfolio advanced to Phase 2 clinical devel
XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights Recognized revenue of $29.4 million Six assets in the Company s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferr
Read more →XOMADISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including stateme
corporate PRESENTATION January 2021 NASDAQ: XOMA A Royalty Aggregation Company Exhibit 99.1 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exch
Read more →XOMAXOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGEN) related to Merck’s advancement of MK-4830 into a Phase 2 study in patients
Read more →XOMAXOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results Company recently earned a $25 million milestone payment as NIS793 advanced to Phase 2 development in advanced p
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results Company recently earned a $25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An undisclosed partner entered Phase 2 d
Read more →XOMAXOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies Inc. (TSXV:BTI.V; OTCQB:BIOAF), associated with the advancement of the enzymes bei
Read more →XOMAXOMA Earns $25 Million Milestone Payment as Anti-TGF Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer
XOMA Earns $25 Million Milestone Payment as Anti-TGF Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer EMERYVILLE, Calif., October 28, 2020 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGF monoclonal antibody licensed fro
Read more →XOMACORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY AUGUST 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements wi
2020 NASDAQ: XOMA 1Exhibit 99.1 CORPORATE PRESENTATION A ROYALTY AGGREGATION COMPANY AUGUST 2020 NASDAQ: XOMA 1 DISCLAIMERS Certain statements in this presentation are forward-looking Potential risks to XOMA meeting these expectations are statements within the meaning of Sectio
Read more →XOMAXOMA Reports Second Quarter 2020 Financial Results Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts
XOMA Reports Second Quarter 2020 Financial Results Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts EMERYVILLE, Calif., August 6, 2020 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), today
Read more →XOMAFORM OF INSTRUCTIONS AS TO USE OF XOMA CORPORATION SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering (the
FORM OF INSTRUCTIONS AS TO USE OF SUBSCRIPTION RIGHTS CERTIFICATES CONSULT THE INFORMATION AGENT, YOUR BANK OR YOUR BROKER AS TO ANY QUESTIONS The following instructions relate to a rights offering (the Rights Offering ) by XOMA Corporation, a Delaware corporation (the Company
Read more →XOMAXOMA Announces Proposed Rights Offering Rights Offering will be available to all shareholders of record on
XOMA Announces Proposed Rights Offering EMERYVILLE, Calif., November 19, 2019 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA) ( XOMA or the Company ) today announced its intent to commence a rights offering pursuant to which the Company would raise approximately $22 million th
Read more →XOMAXOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results
EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today reported its third quarter 2019 financial results. “XOMA’s portfolio of future potential royalty- and milestone-generating assets grew by 25% in the third quarter with the addition of 15
Read more →XOMAXOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L. One of the assets, NIR178, is being de
Read more →XOMAXOMA’s Royalty Portfolio Expands Significantly
EMERYVILLE, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could rece
Read more →XOMAXOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results
Novartis’s iscalimab highlighted at key scientific conferences First patient dosed with gevokizumab in collaborator clinical study Sesen Bio announced intention to initiate Vicinium® BLA filing process in 2019 Royalty and milestone interest acquired in five anti-thrombotic hem
Read more →XOMAXOMA Acquires Royalty Rights to Five Hematology Candidates
EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments associated with five hematology assets from Aronora, Inc. Th
Read more →XOMAXOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient
XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif.,
Read more →XOMACertain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regardin
` corporate PRESENTATION January 2019 With over 35 years of discovery activity, XOMA currently has over three dozen partnered and fully-funded assets with the potential to drive milestone and royalty payments, along with multiple additional programs ready for out-licensing Exhib
Read more →XOMAXOMA Reports Third Quarter 2018 Financial Results
XOMA Reports Third Quarter 2018 Financial Results EMERYVILLE, Calif., November 7, 2018 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator, today announced its third quarter 2018 financial results. The third quarter of 2018 was exciting for XOM
Read more →XOMAXOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte
XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte EMERYVILLE, Calif., September 21, 2018 (GLOBE NEWSWIRE) XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a
Read more →XOMACORPORATE PRESENTATION WITH OVER 35 YEARS OF DISCOVERY ACTIVITY, XOMA CURRENTLY HAS OVER THREE DOZEN PARTNERED AND FULLY-FUNDED ASSETS WITH THE POTENTIAL TO DRIVE MILESTONE AND ROYALTY PAYMENTS, ALONG WITH MULTIPLE ADDIT
CORPORATE PRESENTATION WITH OVER 35 YEARS OF DISCOVERY ACTIVITY, XOMA CURRENTLY HAS OVER THREE DOZEN PARTNERED AND FULLY-FUNDED ASSETS WITH THE POTENTIAL TO DRIVE MILESTONE AND ROYALTY PAYMENTS, ALONG WITH MULTIPLE ADDITIONAL AUGUST 2018 PROGRAMS READY FOR OUT-LICENSING 1 FORWA
Read more →XOMAXOMA Reports First Quarter 2018 Financial Results Current cash balance sufficient to fund operations for multiple years
XOMA Reports First Quarter 2018 Financial Results Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., May 9, 2018 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq: XOMA), a pioneer in the discovery, development and licensing of therapeutic antibo
Read more →XOMAXOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model
EMERYVILLE, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has entered into a flexible $20 million credit facility with Silicon Valley Bank, with availabi
Read more →XOMAXOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Transformed business model to a royalty aggregator with extensive asset portfolio and capital; Added nine new partner-funded p
XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Transformed business model to a royalty aggregator with extensive asset portfolio and capital; Added nine new partner-funded programs in 2017 with potential for milestone and royalty payments; Curren
Read more →XOMAForward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in
Corporate Presentation (Nasdaq: XOMA) JANUARY 2018 Exhibit 99.1 Forward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 193
Read more →XOMAXOMA Reports Third Quarter 2017 Financial Results Validated business strategy with transformational license agreements with Novartis; Expanded portfolio of partner-funded programs with potential for future milestone and
XOMA Reports Third Quarter 2017 Financial Results Validated business strategy with transformational license agreements with Novartis; Expanded portfolio of partner-funded programs with potential for future milestone and royalty payments; Current cash balance sufficient to fund
Read more →XOMAXOMA Reports Second Quarter 2017 Financial Results Executing new corporate strategy leveraging extensive portfolio of partnered programs Earned $10 million milestone payment from a pharmaceutical partner Reduced combined
XOMA Reports Second Quarter 2017 Financial Results Executing new corporate strategy leveraging extensive portfolio of partnered programs Earned $10 million milestone payment from a pharmaceutical partner Reduced combined R&D and G&A expenses 56% year-over-year Current cash ba
Read more →XOMAXOMA Reports First Quarter 2017 Financial Results Established new corporate strategy leveraging extensive portfolio of partnered programs Strengthened balance sheet with BVF Partners investment and substantial debt repay
XOMA Reports First Quarter 2017 Financial Results Established new corporate strategy leveraging extensive portfolio of partnered programs Strengthened balance sheet with BVF Partners investment and substantial debt repayment Reduced combined R&D and G&A expenses 49% year-over-
Read more →XOMAXOMA Reports Fourth Quarter and Full Year 2016 Financial Results Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and val
XOMA Reports Fourth Quarter and Full Year 2016 Financial Results Actions taken in 2016 set the stage for reduced operating costs and capital requirements In early 2017, Company established new strategic direction and value drivers Berkeley, Calif., March 16, 2017 XOMA Corporat
Read more →XOMACowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA)
Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017 Exhibit 99.1 Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017 Forward-looking Statements Certain statements in this presentation are forward-looking statements with
Read more →XOMAXOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update Up to $22 million in revenue generated through sale of roya
XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update BERKELEY, Calif., December 21, 2016 (GLOBE NEWSWIRE) XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and d
Read more →XOMAXOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants
XOMA Announces Pricing of $40.0 Million Registered Offering of Common Stock and Warrants BERKELEY, Calif., December 9, 2014 XOMA Corporation (Nasdaq:XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of com
Read more →XOMAXOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results BERKELEY, Calif., March 4, 2014 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights an
Read more →XOMAXOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Berkeley, CA
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Berkeley, CA - November 20, 2012 -XOMA Corporation (Nasdaq: XOMA) today announced the 837-patient Phase 3 PATH trial (Perindopril Amlodipine for the Treatment of Hyperte
Read more →XOMACompany and Investor Contact: Ashleigh Barreto 510-204-7482 barreto@xoma.com Juliane Snowden The Oratorium Group, LLC jsnowden@oratoriumgroup.com Media Contact: Canale Communications Carolyn Hawley 619-849-5375
XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis BERKELEY, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced its partner, Servier has received authorization to initiate the Servier-sponsored
Read more →XOMA] XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants
XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants BERKELEY, Calif., March 6, 2012 - XOMA Corporation (NASDAQ: XOMA), announced today the pricing of 29,669,154 shares of its common stock and accompanying warrants to purchase one half of a share
Read more →XOMA] XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Berkeley, CA
XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Berkeley, CA - January 17, 2012 -XOMA Corporation (Nasdaq: XOMA) today announced it has acquired U.S. rights to the perindopril franchise from Les Laboratoires Servier, XOMA's partner for i
Read more →XOMA] XOMA Appoints John Varian as Chief Executive Officer Berkeley, CA
XOMA Appoints John Varian as Chief Executive Officer Berkeley, CA - January 5, 2012 - XOMA Corporation (Nasdaq: XOMA) today announced its Board of Directors has appointed John Varian as Chief Executive Officer. Mr. Varian has been serving as the Interim Chief Executive since Aug
Read more →XOMA] XOMA Secures $10 Million Term Loan
XOMA Secures $10 Million Term Loan BERKELEY, Calif., January 3, 2012 - XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of antibody therapeutics, announced that it has entered into a $10.0 million 42-month secured term loan agreement with GE Capital, He
Read more →XOMAXOMA Receives $4 Million for Sale of Royalty Interest in CIMZIA(R)
BERKELEY, Calif., Aug. 18, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA (certolizumab pegol) marketed by UCB S.A. for $4 million to an undiscl
Read more →XOMAXOMA Refinances Royalty-Based Loan Facility for $55 Million
BERKELEY, Calif., May 12, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that it has entered into an amended loan facility under which it has borrowed $55 million from Goldman Sachs Specialty L
Read more →Competitive Position
How XOMA ranks across every disease it competes inCompetitive Position is a premium feature
See how XOMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial